糖尿病药物市场规模、份额和成长分析（按糖尿病类型、药物类型、最终用户和地区划分）－2026-2033年产业预测

预计到 2024 年，全球糖尿病药物市场规模将达到 761.1 亿美元，到 2025 年将达到 813.6 亿美元，到 2033 年将达到 1387.6 亿美元，预测期（2026-2033 年）的复合年增长率为 6.9%。

全球糖尿病治疗市场正经历强劲成长，这主要得益于糖尿病盛行率的不断上升、创新治疗方法的进步以及医疗环境的不断变化。人口老化带来了巨大的市场机会，因为老年人更容易患上糖尿病。都市化和生活方式的改变进一步增加了糖尿病的风险，从而进一步推动了市场扩张。人们对糖尿病的认识不断提高，早期诊断也得到了广泛应用，促进了糖尿病治疗方法的普及。同时，个人化医疗的趋势也使得量身订製的治疗方案成为可能，进而改善治疗效果。人工智慧（AI）、机器学习和物联网（IoT）等技术的整合正在革新药物研发、病患监测和疾病管理。此外，区块链技术确保了病患记录的安全处理，从而提升了信任度和合规性。扩增实境（AR）和虚拟实境（VR）技术正被用于病患教育，帮助患者做出更健康的生活方式选择，并提高治疗依从性。

全球糖尿病药物市场驱动因素

糖尿病（包括第1型和第2型糖尿病）发生率的不断上升，正推动着糖尿病治疗市场持续成长的需求。此外，全球人口老化也加剧了这一趋势，老年人更容易罹患糖尿病。而且，肥胖率的上升，加上久坐不动的生活方式和不健康的饮食习惯，使情况更加恶化，导致胰岛素阻抗和相关代谢紊乱的增加。这些因素共同推动了糖尿病治疗市场的扩张，并凸显了开发有效治疗方法以应对这一普遍存在的健康挑战的迫切需求。

限制全球糖尿病药物市场的因素

全球糖尿病药物市场面临严峻挑战，因为治疗第1型和第2型糖尿病的成本都非常高昂。终身治疗通常需要使用胰岛素、各种药物、治疗方法和血糖值监测设备，对于没有医疗保险或医疗保障不足的人来说，这些费用可能难以负担。这种经济负担，尤其是在缺乏报销的情况下，使得许多患者难以获得所需的糖尿病药物。此外，新型生物製药和个人化药物价格的不断上涨正在阻碍糖尿病治疗领域的创新，加剧了患者和医疗服务提供者面临的困境。

全球糖尿病药物市场趋势

全球糖尿病药物市场正日益拥抱个人化和精准医疗理念，这反映了根据个人基因谱、代谢模式和生活方式因素量身定制治疗方案的重要趋势。这种转变旨在透过解决糖尿病的根本原因并有效降低胰岛素阻抗来提高治疗效果。对个人化解决方案的日益重视不仅改善了患者的治疗效果，也促进了以患者为中心的医疗保健环境的形成。此外，这些先进治疗方法的可近性和可负担性的提高，也促使其在不同患者群体中得到广泛应用，从而推动了糖尿病药物行业的持续成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术评估
• 监管环境
• 客户和购买标准分析
• 管道分析
• 疾病流行病学

全球糖尿病治疗市场规模（依糖尿病类型及复合年增长率划分）（2026-2033 年）

• 1型糖尿病
• 2型糖尿病
• 妊娠糖尿病

全球糖尿病药物市场规模（按药物类型和复合年增长率划分）（2026-2033 年）

• 口服降血糖药
• 注射型抗糖尿病药物

全球糖尿病药物市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 诊所
• 个人使用

全球糖尿病治疗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Novo Nordisk（Denmark）
• Eli Lilly and Company（USA）
• Sanofi（France）
• Merck & Co.（USA）
• AstraZeneca（UK）
• Boehringer Ingelheim（Germany）
• Takeda Pharmaceutical Company（Japan）
• Johnson & Johnson（USA）
• Novartis（Switzerland）
• Bristol Myers Squibb（USA）
• Pfizer（USA）
• Roche（Switzerland）
• Bayer AG（Germany）
• AbbVie（USA）
• Daiichi Sankyo（Japan）
• Gilead Sciences（USA）
• AstraZeneca（UK）
• Amgen（USA）
• GlaxoSmithKline（UK）
• Biocon（India）

结论与建议

Global Diabetes Therapeutics Market size was valued at USD 76.11 Billion in 2024 and is poised to grow from USD 81.36 Billion in 2025 to USD 138.76 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The global diabetes therapeutics market is experiencing robust growth driven by an increasing prevalence of diabetes, innovative treatment advancements, and evolving healthcare dynamics. A rising aging population presents significant opportunities, as older individuals are more susceptible to diabetes. Urbanization and lifestyle changes further amplify diabetes risks, contributing to market expansion. Growing awareness and early diagnosis enhance the adoption of diabetes therapies, while the trend towards personalized medicine allows for tailored treatment solutions that improve efficacy. Technological integration, including AI, machine learning, and IoT, revolutionizes drug discovery, patient monitoring, and disease management. Additionally, blockchain technology ensures secure handling of patient records, fostering trust and regulatory compliance. Augmented and virtual reality are employed for patient education, supporting healthier lifestyle choices and improved treatment adherence.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetes Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetes Therapeutics Market Segments Analysis

Global Diabetes Therapeutics Market is segmented by Diabetes Type, Drug Type, End User and region. Based on Diabetes Type, the market is segmented into Type 1 Diabetes, Type 2 Diabetes and Gestational Diabetes. Based on Drug Type, the market is segmented into Oral Antidiabetics and Injectable Antidiabetics. Based on End User, the market is segmented into Hospitals, Clinics and Personal Use. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetes Therapeutics Market

The growing incidence of diabetes, encompassing both type 1 and type 2, is driving sustained demand within the diabetes therapeutics market. Additionally, the increasing number of elderly individuals globally contributes to this trend, as older adults are more susceptible to developing diabetes. Furthermore, the rise in obesity rates, coupled with sedentary lifestyles and unhealthy dietary choices, exacerbates the situation, leading to higher levels of insulin resistance and related metabolic disorders. Collectively, these factors are propelling the expansion of the diabetes therapeutics market, highlighting the urgent need for effective treatment options to address this widespread health challenge.

Restraints in the Global Diabetes Therapeutics Market

The Global Diabetes Therapeutics market faces considerable challenges due to the high costs associated with managing both type 1 and type 2 diabetes. Lifelong treatment often necessitates the use of insulin, various medications, therapies, and glucose monitoring devices, which can be prohibitively expensive for individuals lacking medical insurance or with inadequate healthcare coverage. This financial burden makes it difficult for many to access the necessary diabetes therapeutics, particularly in the absence of reimbursement options. Furthermore, escalating prices of novel biologics and personalized medicine are hindering innovation within the diabetes therapeutics sector, exacerbating the issues faced by patients and healthcare providers alike.

Market Trends of the Global Diabetes Therapeutics Market

The Global Diabetes Therapeutics market is increasingly embracing personalized and precision medicine approaches, reflecting a significant trend towards tailored treatments that cater to individual genetic profiles, metabolic patterns, and lifestyle factors. This shift aims to address the underlying causes of diabetes, enhancing treatment efficacy by effectively reducing insulin resistance. The growing emphasis on personalized solutions not only aims to improve patient outcomes but also fosters a more patient-centric healthcare landscape. Furthermore, the increasing affordability and improved accessibility of these advanced therapies contribute to their rising popularity, facilitating broader adoption among diverse patient populations and driving sustained growth in the diabetes therapeutics sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Diabetes Therapeutics Market Size by Diabetes Type & CAGR (2026-2033)

• Market Overview
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

Global Diabetes Therapeutics Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Oral Antidiabetics
• Injectable Antidiabetics

Global Diabetes Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Personal Use

Global Diabetes Therapeutics Market Size & CAGR (2026-2033)

• North America (Diabetes Type, Drug Type, End User)
  • US
  • Canada
• Europe (Diabetes Type, Drug Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diabetes Type, Drug Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diabetes Type, Drug Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diabetes Type, Drug Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations